On 4th try, Outlook scores FDA nod for reformulated version of Roche's Avastin for AMD

Roche’s cancer treatment Avastin (bevacizumab) has long been employed as an off-label option for wet age-related macular degeneration (AMD) patients. | Roche’s cancer treatment Avastin has long been employed as an off-label option for wet age-related macular degeneration patients. Now the FDA has endorsed a new formulation of the VEGF inhibitor for regulated use in the U.S. Bringing it to the market is Outlook Therapeutics, which labored through three FDA rejections to finally secure a nod. It will be known commercially as Lytenava.